Approved and investigational SRIF analogs blocking GH secretion
Data adapted from Melmed (2016).
| Agent | Description | Regulatory Status |
|---|---|---|
| Lanreotide autogel | Long-acting lanreotide | Available |
| Administered via deep s.c. injection every 4–6 wk | ||
| Octreotide LAR | Long-acting octreotide | Available |
| Administered via i.m. injection every 4 wk | ||
| Pasireotide LAR | Long-acting pasireotide | Available |
| Administered via i.m. injection every 4 wk | ||
| Octreotide capsules | Octreotide encapsulated with transient permeability enhancer | Completed phase 3 |
| Administered orally twice daily | ||
| CAM2029 | Octreotide bound in liquid crystal matrix | In phase II |
| Administered via s.c. injection at a frequency not yet determined but likely to be every 4 wk | ||
| Veldoreotide (COR-005) | SRIF analog highly selective for GH suppression | In phase II |
| Administered via i.m. injection at a frequency not yet determined but likely to be every 4 wk |